Treating "rebound" emesis following outpatient gynecologic laparoscopy: The efficacy of a two-dose regimen of droperidol ondansetron

Study Objective: To evaluate the efficacy of a two-dose combination of droperidol and ondansetron as compared with single-dose droperidol alone, single-dose combined droperidol and ondansetron, and two-nose droperidol alone for management of postoperative nausea and vomiting PONV among gynecologic laparoscopy outpatients. Design: Randomized, double-blind comparison trial. Setting: Tertiary outpatient gynecologic unit. Patients: Total of 120 female patients scheduled for gynecologic laparoscopy were enrolled. Patients who had experienced nausea or vomiting or who had taken drugs with antiemetic action in the 24-hour period prior to the study as well as breast-feeding mothers, were excluded from participation. Interventions: Patients were assigned to four treatment groups: i) single dose of droperidol 1.25 mg ii) two doses of droperidol 1.25 mg, iii) single dose of droperidol 1.25 mg and ondansetron 4 mg in combination, and iv) two doses of droperidol 1.25 mg and ondansetron on 4,ng in combination. The first dose of antiemetic was administered prior to induction and the second dose was given by infusion 4 hours later, prior to discharge. Measurements and Main Results: A visual analogue scale (VAS, 10 cm) was used to obtain patients' experience of nausea, vomiting, and Pain at 0.5 1.5, 2.5, and 3.5 hours after arrival at the postanesthetic care unit (PACU). Following discharge, approximately 24 hours after arrival at the PACU, the same measures were obtained by a follow-up interview using a verbal 10-point scale. No significant differences in Incidence of PONV were noted among the four treatment groups (p = 0.419). However, both single- and two-dose droperidol and ondansetron combination therapy demonstrated attenuation of PONV severity in the 3.5- to 24-hour postinduction period (p < 0.05). Conclusions: The findings of this study suggest that prophylactic two-dose combined ondansetron and droperidol offers no added benefit over single-dose therapy for routine use in the gynecologic outpatient population. (C) 1999 by Elsevier Science Inc.